Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-/II-study of hyperfractionated-accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.

Trial Profile

Phase I-/II-study of hyperfractionated-accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HART-CIS-CET
  • Most Recent Events

    • 11 Oct 2016 Results (5-years) assessing feasibility, efficacy and safety of combination therapy with cisplatin, cetuximab and hyperfractionated-accelerated radiotherapy (n=74) presented at the 41st European Society for Medical Oncology Congress.
    • 12 Jul 2011 Additional trial identifiers (EudraCT2005-000355-15, KKSH19) identified, trial status is recruiting, planned patient patient number is 74 as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000355-15)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top